Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.37 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555464 | 1.00 | KDM4C (0.37) | KDM4CKDM5AKDM5BCCR2KCNH2 | |
| SCHEMBL23248559 | 0.93 | AXL (0.33) | KDM4CKDM5AKDM5BIRAK4AXL | |
| SCHEMBL30555486 | 0.93 | AXL (0.33) | KDM4CKDM5AKDM5BIRAK4AXL | |
| SCHEMBL30555431 | 0.86 | KDM4C (0.39) | KDM4CKDM5AKDM5BCCR2KCNH2 | |
| SCHEMBL26124766 | 0.86 | KDM4C (0.39) | KDM4CKDM5AKDM5BCCR2KCNH2 | |
| SCHEMBL30555491 | 0.85 | KDM4C (0.40) | KDM4CKDM5AKDM5BCCR2KCNH2 | |
| SCHEMBL26120357 | 0.85 | KDM4C (0.40) | KDM4CKDM5AKDM5BCCR2KCNH2 | |
| SCHEMBL30555471 | 0.84 | KDM4C (0.42) | KDM4CTGFBR1GRM4 | |
| SCHEMBL26123310 | 0.84 | KDM4C (0.42) | KDM4CTGFBR1GRM4 | |
| SCHEMBL30555527 | 0.81 | SYK (0.34) | KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-15 | — | — | US | disclosed |
| EP-4046688-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4046688-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | PARK7, SMN1; SMN2, SNCA | KDM4C 1231/4885KDM5A 1434/4885KDM5B 1160/4885 |
| US-12358879-B2 | Heterocyclic compound | PARK7, SMN1; SMN2, SNCA | KDM4C 1231/4885KDM5A 1434/4885KDM5B 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.